

# UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

JAN 23 1997

012146

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

#### <u>MEMORANDUM</u>

SUBJECT:

VINCLOZOLIN--Tox. Data Submitted Under MRID Nos.

41471005 and 92194019; TRID No. 470148-002

Tox Chem. No. 313C Chemical: 113201

RD Record: [Not provided]
HED Project: D222318 F.S.

(DP Barcode):

FROM:

Irving Mauer, Ph.D., Geneticist

Toxicology Branch-I

Health effects Division (7509C)

TO:

Barry O'Keefe

Special Review and Reregistration Division (7508W)

THRU:

Karen L. Hamernik, Ph.D., Head, Section III

Toxicology Branch-I

Health effects Division (7509C)

Registrant: BASF, RTP (NC)

Request: Review and evaluate the following mutagenicity assay (an Ames Test):

Report on the Study of Vinclozolin (Reg. No. 83/258) (ZNT Test Substance 82/370) in the Ames Test, performed at BASF Laboratories in Ludwigshafen (West Germany), Reg. Doc. No. 83/0228, Final Report dated November, 1983. (MRID 41471005). UNPUBLISHED.

[NB: Two other documents were submitted with this study:

(1) "Report on the Study of Vinclozolin (Reg. No. 83-258) (ZNT Test Substance: 82/370) in the Ames Test", BASF Nov. 14, 1983. (TRID No. 470-148-002), which is an exact duplicate of the above study, and will not be separately reviewed.

(2) Phase 3 Summary of MRID 41471005 (the subject study), MRID 92194-019, which also will not be separately reviewed.

TB CONCLUSION: This Ames Test (MRID 41471005) is ACCEPTABLE, in demonstrating Vinclozolin was negative for induced mutagenicity (reverse mutation) in Ames Testing, and thus satisfies data requirements for FIFRA Test Guideline 84-2a for this type of mutagenicity study.

(ATTACHMENT) DER

# DISK 6:41471005:MAUER:MB

VINCLOZOLIN

SALMONELLA/MAMMALIAN ACTIVATION; GENE MUTATION (84-2)2

EPA Reviewer: Irving Mauer, Ph.D. Hulle Review Section 3, Toxicology Branch I (7509C)

Review Section 3, Toxicology Branch I (7509C) EPA Secondary Reviewer: Karen L. Hamernik, Ph.D.

Review Section 3, Toxicology Branch I (7509C)

for old

Date C

DATA EVALUATION RECORD

STUDY TYPE: Salmonella/Reverse Gene Mutation Assay (Ames Test)

OPPTS 870.5265 [§84-2]

DP BARCODE: D222318

SUBMISSION CODE:

[Not provided]

P.C. CODE: 113

113201

TOX. CHEM. NO.:

323C

TEST MATERIAL (PURITY):

Vinclozolin (98.1% a.i.)

SYNONYMS: RONILAN

CITATION: H. P. Gelbke and G. Engelhardt (1983). Report on the study of Vinclozolin (Reg. No. 83/258) (ZNT Test Substance No. 82/370) in the Ames Test, performed at the BASF Aktiengesellschaft, Department of Toxicology, Ludwigschafen, West Germany. Doc. No. 83/0228, Final Report dated November 1983. MRID 41471005. Unpublished.

SPONSOR: BASF Corporation, RTP (NC).

EXECUTIVE SUMMARY: In a bacterial reverse gene mutation (Ames) assay (MRID 41471005), multiple cultures of Salmonella typhimurium TA strains (TA 1535, 1537, 1538, 98, 100) were exposed to test article in both the standard plate assay (all strains) and by pre-incubation (only TA 100) at concentrations up to 10,000 ug/plate.

No cytotoxicity was observed in any strain tested up to the HDT, and incomplete solubility was evident at 5000 ug/plate and above. No increased incidence of reverse mutation (revertant colonies) over DMSO (solvent) controls was found.

This assay is considered ACCEPTABLE in demonstrating no mutation in Salmonella TA strains, and satisfies data requirements for FIFRA Test Guideline 84-2a for this type of mutagenicity study.

<u>COMPLIANCE</u>: Signed and dated GLP, Quality Assurance, Data Confidentiality, and Flagging statements <u>were</u> provided.

#### I. MATERIALS AND METHODS

#### A. MATERIALS

1.	Test	Material:	Vinclozolin

Description: White powder

Lot/Batch #: 82/370 Purity: 98.1% a.i.

Stability of compound: Said to #be stable in solvent

at 4°C.

CAS #: 50471-44-8

Structure: 3-(3.5-dichlorophenyl)-5-ethenyl-5-

methyl-2.4-oxazolidinedione

Solvent used: Dimethylsulfoxide (DMSO)

Other comments: Test article precipitates out at 5000

uq/plate and above.

#### 2. Control Materials:

Negative: None

Solvent/final concentration: 1%

Positive: Nonactivation:

4-Nitro-o-phenylenediamine, 10 ug/plate for TA 98 and TA 1538

9-Aminoacridine, 100 μg/plate for TA1537

Other: N-methyl-N<sup>1</sup>-nitro-N-nitrosoguanidine (MNNG), 5 ug/plate for TA 100 and TA 1535.

#### Activation:

2-Aminoanthracene (2-anthramine),  $\underline{10}~\mu g/plate$  for all strains

#### 3. Activation: S9 derived from

Aroclor 1254	X induced	<u>X</u>	rat _	X	liver
 phenobarbital	non-induced	<del></del>	mouse		lung
 none		خيستنيد	hamster	r_	other
 other			_		other

Describe S9 mix composition (if purchased, give details):

MgCl2-8mM KCl-33mM Glucose-6-PO4-5mM NADP-4mM P04-buffer-100mM S9-3 volumes

	4.	Test	organisms:	s.	typhimurium	strains	(all	his )	:
--	----	------	------------	----	-------------	---------	------	-------	---

TA97 X TA98 X TA100 TA102 TA104
X TA1535 X TA1537 X TA1538; list any others:
Properly maintained? Y
Checked for appropriate genetic markers: Y

#### 5. Test compound concentrations used:

Nonactivated conditions: 100-10,000 ug/plate (4 plates

per dose)

Activated conditions: 100-10,000 ug/plate (4 plates

per dose)

#### B. TEST PERFORMANCE

#### 1. Type of Salmonella assay:

X standard plate test, all strains
X pre-incubation (8 minutes), TA 100 only
Prival modification

\_\_\_ spot test

\_\_\_ other (describe)

 Protocol: Procedure for the standard plate test was based upon the method of Ames (1973, 1975); that for the pre-incubation assay on Yahagi et al. (1977) and Matsushima et al. (1980).

#### C. REPORTED RESULTS:

### 1. Preliminary cytotoxicity assay:

There was no cytotoxicity in any strain up to the HDT, 10,000 ug/plate, with/without S9-activation. Incomplete solubility was observed at concentrations of 5,000 ug/plate and above.

- 2. <u>Mutagenicity assay</u>: In neither plate assay with all strains with/without activation, nor in the pre-incubation assay with TA 100 ± S9 activation, was there any increase in <u>his</u>+ revertant colonies over background (DMSO solvent control Report Tables 1, 2 attached here). In contrast, all positive control plates registered the appropriate increased revertents.
- D. <u>REVIEWER'S DISCUSSION/CONCLUSIONS</u>: This assay was performed with conventionally recognized procedures to yield valid results. We agree with the investigators' conclusions that under the conditions this study, vinclozolin was not mutagenic in inducing reversions at the histidine locus of the Ames battery of TA strains.

- E. Was test performed under GLPs (is a quality assurance statement present)?  $\ensuremath{\mathtt{Y}}$ 
  - F. Appendix attached? Y, Data Tables

# SALMONELLA/MAMMALIAN ACTIVATION; GENE MUTATION (84-2)

Disk 6: 41471005.DER:MAUER:mb

VINCLOZOLIN

# TON Ros. 012140

Page is not included in this copy.
Pages 9 through 10 are not included.
The material not included contains the following type of information:
Identity of product inert ingredients.
Identity of product impurities.
Description of the product manufacturing process.
Description of quality control procedures.
Identity of the source of product ingredients.
Sales or other commercial/financial information.
A draft product label.
The product confidential statement of formula.
Information about a pending registration action.
FIFRA registration data.
The document is a duplicate of page(s)
The document is not responsive to the request.
The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.